Health-Related Quality Of Life (Hrqol) Benefits Of Enzalutamide In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc): An In-Depth Analysis Of Eq-5d Data From The Prevail Trial.

Devlin, N; Herdman, M; Pavesi, M; Phung, D; Naidoo, S; Beer, T M; Tombal, Bertrand; Loriot, Y; Ivanescu, C; Parli, T; Balk, M; Holmstrom, S

doi:10.1016/j.jval.2015.09.1270

Health-Related Quality Of Life (Hrqol) Benefits Of Enzalutamide In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc): An In-Depth Analysis Of Eq-5d Data From The Prevail Trial.

Devlin, N

;

Herdman, M

;

Pavesi, M

;

Phung, D

;

Holmstrom, S

;et.al.

(2015) IPSOR 18th Annual European Congress — Location: Milan, Italy (7.November.2015)

Files

Devlin-2015-HealthrelatedqualityoflifeCongressparticipation.pdf

Restricted Access
Adobe PDF
51.21 KB

Request a copy

Details

Authors

Devlin, N
Author
Herdman, M
Author
Pavesi, M
Author
Phung, D
Author
Tombal, BertrandUCLouvain
Author
Holmstrom, S
Author

Affiliations

Citations

APA
Chicago
FWB

Devlin, N., Herdman, M., Pavesi, M., Phung, D., Naidoo, S., Beer, T. M., Tombal, B., Loriot, Y., Ivanescu, C., Parli, T., Balk, M., & Holmstrom, S. (2015). Health-Related Quality Of Life (Hrqol) Benefits Of Enzalutamide In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc): An In-Depth Analysis Of Eq-5d Data From The Prevail Trial. Value in health, 18(7), A475. https://doi.org/10.1016/j.jval.2015.09.1270 (Original work published 2015)